Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease

Circulation Research

Volumn 118, Issue 11, 2016, Pages 1786-1807

  Fuster, José J ^a   Ouchi, Noriyuki ^a   Gokce, Noyan ^b   Walsh, Kenneth ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

adipokines; adipose tissue; atherosclerosis; myocardial infarction; obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN RECEPTOR; COMPLEMENT COMPONENT C1Q; INTERLEUKIN 6; LECTIN; LEPTIN; OMENTIN 1; RESISTIN; SECRETED FRIZZLED RELATED PROTEIN 5; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL INFILTRATION; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DOWN REGULATION; HUMAN; IMMUNOCOMPETENT CELL; ISCHEMIC HEART DISEASE; MICROENVIRONMENT; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; UPREGULATION; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; METABOLISM; PATHOLOGY; TUMOR MICROENVIRONMENT;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; CELLULAR MICROENVIRONMENT; HUMANS; OBESITY;

EID: 84971280245     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.306885     Document Type: Review

References (358)

1. Archer E, Shook RP, Thomas DM, Church TS, Katzmarzyk PT, Hébert JR, McIver KL, Hand GA, Lavie CJ, Blair SN, 45-Year trends in women's use of time and household management energy expenditure. PLoS One 2013 8 e56620. doi: 10.1371/journal.pone.0056620
2. Church TS, Thomas DM, Tudor-Locke C, Katzmarzyk PT, Earnest CP, Rodarte RQ, Martin CK, Blair SN, Bouchard C, Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. PLoS One 2011 6 e19657. doi: 10.1371/journal.pone.0019657
3. Taubes G, The science of obesity: what do we really know about what makes us fat? An essay by Gary Taubes. BMJ 2013 346 f1050
4. Prospective Studies Collaboration Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009 373 1083 96
5. Baba S, Jacene HA, Engles JM, Honda H, Wahl RL, CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med 2010 51 246 250. doi: 10.2967/jnumed.109.068775
6. Rosenquist KJ, Massaro JM, Pedley A, Long MT, Kreger BE, Vasan RS, Murabito JM, Hoffmann U, Fox CS, Fat quality and incident cardiovascular disease, all-cause mortality, and cancer mortality. J Clin Endocrinol Metab 2015 100 227 234. doi: 10.1210/jc.2013-4296
7. Rosenquist KJ, Pedley A, Massaro JM, Therkelsen KE, Murabito JM, Hoffmann U, Fox CS, Visceral and subcutaneous fat quality and cardiometabolic risk. J AM COLL CARDIOL. Cardiovasc Imaging 2013 6 762 771. doi: 10.1016/j.jcmg.2012.11.021
8. Abraham TM, Pedley A, Massaro JM, Hoffmann U, Fox CS, Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. Circulation 2015 132 1639 1647. doi: 10.1161/CIRCULATIONAHA.114.015000
9. Bays HE, Adiposopathy is "sick fat" a cardiovascular disease? J Am Coll Cardiol 2011 57 2461 2473. doi: 10.1016/j.jacc.2011.02.038
10. Lê KA, Mahurkar S, Alderete TL, Hasson RE, Adam TC, Kim JS, Beale E, Xie C, Greenberg AS, Allayee H, Goran MI, Subcutaneous adipose tissue macrophage infiltration is associated with hepatic and visceral fat deposition, hyperinsulinemia, and stimulation of NF-κB stress pathway. Diabetes 2011 60 2802 2809. doi: 10.2337/db10-1263
11. Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, McDonnell M, Hess D, Joseph L, Gokce N, Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2008 28 1654 1659. doi: 10.1161/ATVBAHA.108.170316
12. Farb MG, Bigornia S, Mott M, Tanriverdi K, Morin KM, Freedman JE, Joseph L, Hess DT, Apovian CM, Vita JA, Gokce N, Reduced adipose tissue inflammation represents an intermediate cardiometabolic phenotype in obesity. J Am Coll Cardiol 2011 58 232 237. doi: 10.1016/j.jacc.2011.01.051
13. Bigornia SJ, Farb MG, Mott MM, Hess DT, Carmine B, Fiscale A, Joseph L, Apovian CM, Gokce N, Relation of depot-specific adipose inflammation to insulin resistance in human obesity. Nutr Diabetes 2012 2 e30. doi: 10.1038/nutd.2012.3
14. Thompson D, Karpe F, Lafontan M, Frayn K, Physical activity and exercise in the regulation of human adipose tissue physiology. Physiol Rev 2012 92 157 191. doi: 10.1152/physrev.00012.2011
15. Lavie CJ, De Schutter A, Milani RV, Healthy obese versus unhealthy lean: the obesity paradox. Nat Rev Endocrinol 2015 11 55 62. doi: 10.1038/nrendo.2014.165
16. McLaughlin T, Lamendola C, Liu A, Abbasi F, Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab 2011 96 E1756 E1760. doi: 10.1210/jc.2011-0615
17. Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA, Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012 308 1150 1159. doi: 10.1001/2012.jama.11132
18. Arkin JM, Alsdorf R, Bigornia S, Palmisano J, Beal R, Istfan N, Hess D, Apovian CM, Gokce N, Relation of cumulative weight burden to vascular endothelial dysfunction in obesity. Am J Cardiol 2008 101 98 101. doi: 10.1016/j.amjcard.2007.07.055
19. Goodpaster BH, Krishnaswami S, Harris TB, Katsiaras A, Kritchevsky SB, Simonsick EM, Nevitt M, Holvoet P, Newman AB, Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 2005 165 777 783. doi: 10.1001/archinte.165.7.777
20. Hashimoto M, Akishita M, Eto M, Kozaki K, Ako J, Sugimoto N, Yoshizumi M, Toba K, Ouchi Y, The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation. Int J Obes Relat Metab Disord 1998 22 477 484
21. Parikh NI, Keyes MJ, Larson MG, Pou KM, Hamburg NM, Vita JA, O'Donnell CJ, Vasan RS, Mitchell GF, Hoffmann U, Fox CS, Benjamin EJ, Visceral and subcutaneous adiposity and brachial artery vasodilator function. Obesity (Silver Spring) 2009 17 2054 2059. doi: 10.1038/oby.2009.60
22. Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S, Sinopoli F, Mattioli PL, Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 2001 50 159 165
23. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, Keaney JF Jr, Meigs JB, Lipinska I, Kathiresan S, Murabito JM, O'Donnell CJ, Benjamin EJ, Fox CS, Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007 116 1234 1241. doi: 10.1161/CIRCULATIONAHA.107.710509
24. Shah RV, Murthy VL, Abbasi SA, Blankstein R, Kwong RY, Goldfine AB, Jerosch-Herold M, Lima JA, Ding J, Allison MA, Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study. J AM COLL CARDIOL. Cardiovasc Imaging 2014 7 1221 1235. doi: 10.1016/j.jcmg.2014.07.017
25. Tchernof A, Després JP, Pathophysiology of human visceral obesity: An update. Physiol Rev 2013 93 359 404. doi: 10.1152/physrev.00033.2011
26. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, Coutinho T, Jensen MD, Roger VL, Singh P, Lopez-Jimenez F, Normal-weight central obesity: implications for total and cardiovascular mortality. Ann Intern Med 2015 163 827 835. doi: 10.7326/M14-2525
27. Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irlbeck T, Meigs JB, Sutherland P, D'Agostino RB Sr, O'Donnell CJ, Fox CS, Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity (Silver Spring) 2010 18 2191 2198. doi: 10.1038/oby.2010.59
28. Nicklas BJ, Penninx BW, Ryan AS, Berman DM, Lynch NA, Dennis KE, Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women. Diabetes Care 2003 26 1413 1420
29. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L, Visceral adiposity and risk of type 2 diabetes: A prospective study among Japanese Americans. Diabetes Care 2000 23 465 471
30. Porter SA, Massaro JM, Hoffmann U, Vasan RS, O'Donnel CJ, Fox CS, Abdominal subcutaneous adipose tissue: A protective fat depot? Diabetes Care 2009 32 1068 1075. doi: 10.2337/dc08-2280
31. Snijder MB, Visser M, Dekker JM, Goodpaster BH, Harris TB, Kritchevsky SB, De Rekeneire N, Kanaya AM, Newman AB, Tylavsky FA, Seidell JC, Health ABC Study Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. Diabetologia 2005 48 301 308. doi: 10.1007/s00125-004-1637-7
32. Ibrahim MM, Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010 11 11 18. doi: 10.1111/j.1467-789X.2009.00623.x.
33. Park HS, Park JY, Yu R, Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-Alpha and IL-6. Diabetes Res Clin Pract 2005 69 29 35. doi: 10.1016/j.diabres.2004.11.007
34. Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM, Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 2003 13 674 682
35. Tsigos C, Kyrou I, Chala E, Tsapogas P, Stavridis JC, Raptis SA, Katsilambros N, Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 1999 48 1332 1335
36. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB, Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999 282 2131 2135
37. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S, Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007 56 1010 1013. doi: 10.2337/db06-1656
38. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD, Splanchnic lipolysis in human obesity. J Clin Invest 2004 113 1582 1588. doi: 10.1172/JCI21047
39. Woo KS, Chook P, Yu CW, Sung RY, Qiao M, Leung SS, Lam CW, Metreweli C, Celermajer DS, Overweight in children is associated with arterial endothelial dysfunction and intima-media thickening. Int J Obes Relat Metab Disord 2004 28 852 857. doi: 10.1038/sj.ijo.0802539
40. Gealekman O, Guseva N, Hartigan C, Apotheker S, Gorgoglione M, Gurav K, Tran KV, Straubhaar J, Nicoloro S, Czech MP, Thompson M, Perugini RA, Corvera S, Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation 2011 123 186 194. doi: 10.1161/CIRCULATIONAHA.110.970145
41. Farb MG, Ganley-Leal L, Mott M, Liang Y, Ercan B, Widlansky ME, Bigornia SJ, Fiscale AJ, Apovian CM, Carmine B, Hess DT, Vita JA, Gokce N, Arteriolar function in visceral adipose tissue is impaired in human obesity. Arterioscler Thromb Vasc Biol 2012 32 467 473. doi: 10.1161/ATVBAHA.111.235846
42. Farb MG, Tiwari S, Karki S, Ngo DT, Carmine B, Hess DT, Zuriaga MA, Walsh K, Fetterman JL, Hamburg NM, Vita JA, Apovian CM, Gokce N, Cyclooxygenase inhibition improves endothelial vasomotor dysfunction of visceral adipose arterioles in human obesity. Obesity (Silver Spring) 2014 22 349 355. doi: 10.1002/oby.20505
43. Alvehus M, Burén J, Sjöström M, Goedecke J, Olsson T, The human visceral fat depot has a unique inflammatory profile. Obesity (Silver Spring) 2010 18 879 883. doi: 10.1038/oby.2010.22
44. Fuster JJ, Zuriaga MA, Ngo DT, Farb MG, Aprahamian T, Yamaguchi TP, Gokce N, Walsh K, Noncanonical Wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction independent of adipose tissue expansion. Diabetes 2015 64 1235 1248. doi: 10.2337/db14-1164
45. Ledoux S, Queguiner I, Msika S, Calderari S, Rufat P, Gasc JM, Corvol P, Larger E, Angiogenesis associated with visceral and subcutaneous adipose tissue in severe human obesity. Diabetes 2008 57 3247 3257. doi: 10.2337/db07-1812
46. Samaras K, Botelho NK, Chisholm DJ, Lord RV, Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity (Silver Spring) 2010 18 884 889. doi: 10.1038/oby.2009.443
47. Chau YY, Bandiera R, Serrels A, Martínez-Estrada OM, Qing W, Lee M, Slight J, Thornburn A, Berry R, McHaffie S, Stimson RH, Walker BR, Chapuli RM, Schedl A, Hastie N, Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source. Nat Cell Biol 2014 16 367 375. doi: 10.1038/ncb2922
48. Gesta S, Blüher M, Yamamoto Y, Norris AW, Berndt J, Kralisch S, Boucher J, Lewis C, Kahn CR, Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci U S A 2006 103 6676 6681. doi: 10.1073/pnas.0601752103
49. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, Kolodny GM, Kahn CR, Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009 360 1509 1517. doi: 10.1056/NEJMoa0810780
50. Pfannenberg C, Werner MK, Ripkens S, Stef I, Deckert A, Schmadl M, Reimold M, Häring HU, Claussen CD, Stefan N, Impact of age on the relationships of brown adipose tissue with sex and adiposity in humans. Diabetes 2010 59 1789 1793. doi: 10.2337/db10-0004
51. Shimizu I, Aprahamian T, Kikuchi R, Shimizu A, Papanicolaou KN, MacLauchlan S, Maruyama S, Walsh K, Vascular rarefaction mediates whitening of brown fat in obesity. J Clin Invest 2014 124 2099 2112. doi: 10.1172/JCI71643
52. Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, Rothenberg FG, Neltner B, Romig-Martin SA, Dickson EW, Rudich S, Weintraub NL, Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res 2009 104 541 549. doi: 10.1161/CIRCRESAHA.108.182998
53. Police SB, Thatcher SE, Charnigo R, Daugherty A, Cassis LA, Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol 2009 29 1458 1464. doi: 10.1161/ATVBAHA.109.192658
54. Padilla J, Jenkins NT, Vieira-Potter VJ, Laughlin MH, Divergent phenotype of rat thoracic and abdominal perivascular adipose tissues. Am J Physiol Regul Integr Comp Physiol 2013 304 R543 R552. doi: 10.1152/ajpregu.00567.2012
55. Fitzgibbons TP, Kogan S, Aouadi M, Hendricks GM, Straubhaar J, Czech MP, Similarity of mouse perivascular and brown adipose tissues and their resistance to diet-induced inflammation. Am J Physiol Heart Circ Physiol 2011 301 H1425 H1437. doi: 10.1152/ajpheart.00376.2011
56. Gustafson B, Smith U, Regulation of white adipogenesis and its relation to ectopic fat accumulation and cardiovascular risk. Atherosclerosis 2015 241 27 35. doi: 10.1016/j.atherosclerosis.2015.04.812
57. Kim JY, van de Wall E, Laplante M, Obesity-Associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007 117 2621 2637. doi: 10.1172/JCI31021
58. Kusminski CM, Holland WL, Sun K, Park J, Spurgin SB, Lin Y, Askew GR, Simcox JA, McClain DA, Li C, Scherer PE, MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat Med 2012 18 1539 1549. doi: 10.1038/nm.2899
59. Wang QA, Tao C, Gupta RK, Scherer PE, Tracking adipogenesis during white adipose tissue development, expansion and regeneration. Nat Med 2013 19 1338 1344. doi: 10.1038/nm.3324
60. Cildir G, Akincilar SC, Tergaonkar V, Chronic adipose tissue inflammation: All immune cells on the stage. Trends Mol Med 2013 19 487 500. doi: 10.1016/j.molmed.2013.05.001
61. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr, Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003 112 1796 1808. doi: 10.1172/JCI19246
62. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H, Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003 112 1821 1830. doi: 10.1172/JCI19451
63. Amano SU, Cohen JL, Vangala P, Tencerova M, Nicoloro SM, Yawe JC, Shen Y, Czech MP, Aouadi M, Local proliferation of macrophages contributes to obesity-Associated adipose tissue inflammation. Cell Metab 2014 19 162 171. doi: 10.1016/j.cmet.2013.11.017
64. Lumeng CN, Bodzin JL, Saltiel AR, Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007 117 175 184. doi: 10.1172/JCI29881
65. Kratz M, Coats BR, Hisert KB, Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab 2014 20 614 625. doi: 10.1016/j.cmet.2014.08.010
66. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Györi G, Zlabinger GJ, Stulnig TM, Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 2007 31 1420 1428. doi: 10.1038/sj.ijo.0803632
67. Xu X, Grijalva A, Skowronski A, van Eijk M, Serlie MJ, Ferrante AW Jr, Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation. Cell Metab 2013 18 816 830. doi: 10.1016/j.cmet.2013.11.001
68. McNelis JC, Olefsky JM, Macrophages, immunity, and metabolic disease. Immunity 2014 41 36 48. doi: 10.1016/j.immuni.2014.05.010
69. Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG, Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 2008 8 301 309. doi: 10.1016/j.cmet.2008.08.015
70. Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, Wabitsch M, O'Brien PE, Harrison LC, Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 2010 59 1648 1656. doi: 10.2337/db09-0287
71. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK, Chawla A, Locksley RM, Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011 332 243 247. doi: 10.1126/science.1201475
72. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara K, Ueki K, Sugiura S, Yoshimura K, Kadowaki T, Nagai R, CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009 15 914 920. doi: 10.1038/nm.1964
73. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, Wang Y, Zielenski J, Mastronardi F, Maezawa Y, Drucker DJ, Engleman E, Winer D, Dosch HM, Normalization of obesity-Associated insulin resistance through immunotherapy. Nat Med 2009 15 921 929. doi: 10.1038/nm.2001
74. Winer DA, Winer S, Shen L, B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med 2011 17 610 617. doi: 10.1038/nm.2353
75. Singer K, DelProposto J, Morris DL, Zamarron B, Mergian T, Maley N, Cho KW, Geletka L, Subbaiah P, Muir L, Martinez-Santibanez G, Lumeng CN, Diet-induced obesity promotes myelopoiesis in hematopoietic stem cells. Mol Metab 2014 3 664 675. doi: 10.1016/j.molmet.2014.06.005
76. Nagareddy PR, Kraakman M, Masters SL, Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab 2014 19 821 835. doi: 10.1016/j.cmet.2014.03.029
77. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine AB, Benoist C, Shoelson S, Mathis D, Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009 15 930 939. doi: 10.1038/nm.2002
78. Ip BC, Hogan AE, Nikolajczyk BS, Lymphocyte roles in metabolic dysfunction: of men and mice. Trends Endocrinol Metab 2015 26 91 100. doi: 10.1016/j.tem.2014.12.001
79. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS, Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005 46 2347 2355. doi: 10.1194/jlr.M500294-JLR200
80. Murano I, Barbatelli G, Parisani V, Latini C, Muzzonigro G, Castellucci M, Cinti S, Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 2008 49 1562 1568. doi: 10.1194/jlr.M800019-JLR200
81. Elgazar-Carmon V, Rudich A, Hadad N, Levy R, Neutrophils transiently infiltrate intra-Abdominal fat early in the course of high-fat feeding. J Lipid Res 2008 49 1894 1903. doi: 10.1194/jlr.M800132-JLR200
82. Mansuy-Aubert V, Zhou QL, Xie X, Imbalance between neutrophil elastase and its inhibitor α1-Antitrypsin in obesity alters insulin sensitivity, inflammation, and energy expenditure. Cell Metab 2013 17 534 548. doi: 10.1016/j.cmet.2013.03.005
83. Talukdar S, Oh da Y, Bandyopadhyay G, Li D, Xu J, McNelis J, Lu M, Li P, Yan Q, Zhu Y, Ofrecio J, Lin M, Brenner MB, Olefsky JM, Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med 2012 18 1407 1412. doi: 10.1038/nm.2885
84. Liu J, Divoux A, Sun J, Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009 15 940 945. doi: 10.1038/nm.1994
85. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I, Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007 56 901 911. doi: 10.2337/db06-0911
86. Pasarica M, Rood J, Ravussin E, Schwarz JM, Smith SR, Redman LM, Reduced oxygenation in human obese adipose tissue is associated with impaired insulin suppression of lipolysis. J Clin Endocrinol Metab 2010 95 4052 4055. doi: 10.1210/jc.2009-2377
87. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR, Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009 58 718 725. doi: 10.2337/db08-1098
88. Ye J, Gao Z, Yin J, He Q, Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007 293 E1118 E1128. doi: 10.1152/ajpendo.00435.2007
89. Sun K, Wernstedt Asterholm I, Kusminski CM, Bueno AC, Wang ZV, Pollard JW, Brekken RA, Scherer PE, Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci U S A 2012 109 5874 5879. doi: 10.1073/pnas.1200447109
90. Elias I, Franckhauser S, Ferré T, Vilà L, Tafuro S, Muñoz S, Roca C, Ramos D, Pujol A, Riu E, Ruberte J, Bosch F, Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes 2012 61 1801 1813. doi: 10.2337/db11-0832
91. Sung HK, Doh KO, Son JE, Park JG, Bae Y, Choi S, Nelson SM, Cowling R, Nagy K, Michael IP, Koh GY, Adamson SL, Pawson T, Nagy A, Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab 2013 17 61 72. doi: 10.1016/j.cmet.2012.12.010
92. Sun K, Kusminski CM, Luby-Phelps K, Spurgin SB, An YA, Wang QA, Holland WL, Scherer PE, Brown adipose tissue derived VEGF-A modulates cold tolerance and energy expenditure. Mol Metab 2014 3 474 483. doi: 10.1016/j.molmet.2014.03.010
93. Nedergaard J, Cannon B, UCP1 mRNA does not produce heat. Biochim Biophys Acta 2013 1831 943 949. doi: 10.1016/j.bbalip.2013.01.009
94. Cao Y, Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov 2010 9 107 115. doi: 10.1038/nrd3055
95. Goossens GH, Bizzarri A, Venteclef N, Essers Y, Cleutjens JP, Konings E, Jocken JW, Cajlakovic M, Ribitsch V, Clément K, Blaak EE, Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation 2011 124 67 76. doi: 10.1161/CIRCULATIONAHA.111.027813
96. Gealekman O, Burkart A, Chouinard M, Nicoloro SM, Straubhaar J, Corvera S, Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production. Am J Physiol Endocrinol Metab 2008 295 E1056 E1064. doi: 10.1152/ajpendo.90345.2008
97. Trayhurn P, Wang B, Wood IS, Hypoxia in adipose tissue: A basis for the dysregulation of tissue function in obesity? Br J Nutr 2008 100 227 235. doi: 10.1017/S0007114508971282
98. Ngo DT, Farb MG, Kikuchi R, Karki S, Tiwari S, Bigornia SJ, Bates DO, LaValley MP, Hamburg NM, Vita JA, Hess DT, Walsh K, Gokce N, Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. Circulation 2014 130 1072 1080. doi: 10.1161/CIRCULATIONAHA.113.008171
99. Villaret A, Galitzky J, Decaunes P, Estève D, Marques MA, Sengenès C, Chiotasso P, Tchkonia T, Lafontan M, Kirkland JL, Bouloumié A, Adipose tissue endothelial cells from obese human subjects: differences among depots in angiogenic, metabolic, and inflammatory gene expression and cellular senescence. Diabetes 2010 59 2755 2763. doi: 10.2337/db10-0398
100. Zhang QX, Magovern CJ, Mack CA, Budenbender KT, Ko W, Rosengart TK, Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res 1997 67 147 154. doi: 10.1006/jsre.1996.4983
101. Kikuchi R, Nakamura K, MacLauchlan S, An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. Nat Med 2014 20 1464 1471. doi: 10.1038/nm.3703
102. Nishimura S, Manabe I, Nagasaki M, Seo K, Yamashita H, Hosoya Y, Ohsugi M, Tobe K, Kadowaki T, Nagai R, Sugiura S, In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J Clin Invest 2008 118 710 721. doi: 10.1172/JCI33328
103. Dharmashankar K, Welsh A, Wang J, Kizhakekuttu TJ, Ying R, Gutterman DD, Widlansky ME, Nitric oxide synthase-dependent vasodilation of human subcutaneous arterioles correlates with noninvasive measurements of endothelial function. Am J Hypertens 2012 25 528 534. doi: 10.1038/ajh.2012.8
104. Freed JK, Beyer AM, LoGiudice JA, Hockenberry JC, Gutterman DD, Ceramide changes the mediator of flow-induced vasodilation from nitric oxide to hydrogen peroxide in the human microcirculation. Circ Res 2014 115 525 532. doi: 10.1161/CIRCRESAHA.115.303881
105. Grassi G, Seravalle G, Scopelliti F, Dell'Oro R, Fattori L, Quarti-Trevano F, Brambilla G, Schiffrin EL, Mancia G, Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity. Obesity (Silver Spring) 2010 18 92 98. doi: 10.1038/oby.2009.195
106. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, Laing I, Yates AP, Pemberton PW, Malik RA, Heagerty AM, Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009 119 1661 1670. doi: 10.1161/CIRCULATIONAHA.108.821181
107. Grizelj I, Cavka A, Bian JT, Szczurek M, Robinson A, Shinde S, Nguyen V, Braunschweig C, Wang E, Drenjancevic I, Phillips SA, Reduced flow-And acetylcholine-induced dilations in visceral compared to subcutaneous adipose arterioles in human morbid obesity. Microcirculation 2015 22 44 53. doi: 10.1111/micc.12164
108. Kizhakekuttu TJ, Wang J, Dharmashankar K, Ying R, Gutterman DD, Vita JA, Widlansky ME, Adverse alterations in mitochondrial function contribute to type 2 diabetes mellitus-related endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2012 32 2531 2539. doi: 10.1161/ATVBAHA.112.256024
109. Virdis A, Duranti E, Rossi C, Dell'Agnello U, Santini E, Anselmino M, Chiarugi M, Taddei S, Solini A, Tumour necrosis factor-Alpha participates on the endothelin-1/nitric oxide imbalance in small arteries from obese patients: role of perivascular adipose tissue. Eur Heart J 2015 36 784 794. doi: 10.1093/eurheartj/ehu072
110. Virdis A, Santini F, Colucci R, Duranti E, Salvetti G, Rugani I, Segnani C, Anselmino M, Bernardini N, Blandizzi C, Salvetti A, Pinchera A, Taddei S, Vascular generation of tumor necrosis factor-α reduces nitric oxide availability in small arteries from visceral fat of obese patients. J Am Coll Cardiol 2011 58 238 247. doi: 10.1016/j.jacc.2011.01.050
111. Ohman MK, Shen Y, Obimba CI, Wright AP, Warnock M, Lawrence DA, Eitzman DT, Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008 117 798 805. doi: 10.1161/CIRCULATIONAHA.107.717595
112. Karki S, Farb MG, Ngo DT, Myers S, Puri V, Hamburg NM, Carmine B, Hess DT, Gokce N, Forkhead box O-1 modulation improves endothelial insulin resistance in human obesity. Arterioscler Thromb Vasc Biol 2015 35 1498 1506. doi: 10.1161/ATVBAHA.114.305139
113. Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, Zhang BB, Bonaldo P, Chua S, Scherer PE, Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 2009 29 1575 1591. doi: 10.1128/MCB.01300-08
114. Guglielmi V, Cardellini M, Cinti F, Corgosinho F, Cardolini I, D'Adamo M, Zingaretti MC, Bellia A, Lauro D, Gentileschi P, Federici M, Cinti S, Sbraccia P, Omental adipose tissue fibrosis and insulin resistance in severe obesity. Nutr Diabetes 2015 5 e175. doi: 10.1038/nutd.2015.22
115. Divoux A, Tordjman J, Lacasa D, Veyrie N, Hugol D, Aissat A, Basdevant A, Guerre-Millo M, Poitou C, Zucker JD, Bedossa P, Clément K, Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes 2010 59 2817 2825. doi: 10.2337/db10-0585
116. Spencer M, Unal R, Zhu B, Rasouli N, McGehee RE Jr, Peterson CA, Kern PA, Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. J Clin Endocrinol Metab 2011 96 E1990 E1998. doi: 10.1210/jc.2011-1567
117. Halberg N, Khan T, Trujillo ME, Wernstedt-Asterholm I, Attie AD, Sherwani S, Wang ZV, Landskroner-Eiger S, Dineen S, Magalang UJ, Brekken RA, Scherer PE, Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 2009 29 4467 4483. doi: 10.1128/MCB.00192-09
118. Sun K, Halberg N, Khan M, Magalang UJ, Scherer PE, Selective inhibition of hypoxia-inducible factor 1α ameliorates adipose tissue dysfunction. Mol Cell Biol 2013 33 904 917. doi: 10.1128/MCB.00951-12
119. Sun K, Park J, Gupta OT, Holland WL, Auerbach P, Zhang N, Goncalves Marangoni R, Nicoloro SM, Czech MP, Varga J, Ploug T, An Z, Scherer PE, Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat Commun 2014 5 3485. doi: 10.1038/ncomms4485
120. Iwayama T, Steele C, Yao L, Dozmorov MG, Karamichos D, Wren JD, Olson LE, PDGFRα signaling drives adipose tissue fibrosis by targeting progenitor cell plasticity. Genes Dev 2015 29 1106 1119. doi: 10.1101/gad.260554.115
121. Nakamura K, Fuster JJ, Walsh K, Adipokines: A link between obesity and cardiovascular disease. J Cardiol 2014 63 250 259. doi: 10.1016/j.jjcc.2013.11.006
122. Ouchi N, Parker JL, Lugus JJ, Walsh K, Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011 11 85 97. doi: 10.1038/nri2921
123. Cook KS, Min HY, Johnson D, Chaplinsky RJ, Flier JS, Hunt CR, Spiegelman BM, Adipsin: A circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 1987 237 402 405
124. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW, Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004 145 2273 2282. doi: 10.1210/en.2003-1336
125. Dahlman I, Elsen M, Tennagels N, Korn M, Brockmann B, Sell H, Eckel J, Arner P, Functional annotation of the human fat cell secretome. Arch Physiol Biochem 2012 118 84 91. doi: 10.3109/13813455.2012.685745
126. Roca-Rivada A, Alonso J, Al-Massadi O, Castelao C, Peinado JR, Seoane LM, Casanueva FF, Pardo M, Secretome analysis of rat adipose tissues shows location-specific roles for each depot type. J Proteomics 2011 74 1068 1079. doi: 10.1016/j.jprot.2011.03.010
127. Takaoka M, Nagata D, Kihara S, Shimomura I, Kimura Y, Tabata Y, Saito Y, Nagai R, Sata M, Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ Res 2009 105 906 911. doi: 10.1161/CIRCRESAHA.109.199653
128. Verhagen SN, Vink A, van der Graaf Y, Visseren FL, Coronary perivascular adipose tissue characteristics are related to atherosclerotic plaque size and composition. A post-mortem study. Atherosclerosis 2012 225 99 104. doi: 10.1016/j.atherosclerosis.2012.08.031
129. Owen MK, Witzmann FA, McKenney ML, Lai X, Berwick ZC, Moberly SP, Alloosh M, Sturek M, Tune JD, Perivascular adipose tissue potentiates contraction of coronary vascular smooth muscle: influence of obesity. Circulation 2013 128 9 18. doi: 10.1161/CIRCULATIONAHA.112.001238
130. Chang L, Villacorta L, Li R, Hamblin M, Xu W, Dou C, Zhang J, Wu J, Zeng R, Chen YE, Loss of perivascular adipose tissue on peroxisome proliferator-Activated receptor-γ deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation 2012 126 1067 1078. doi: 10.1161/CIRCULATIONAHA.112.104489
131. Lehman SJ, Massaro JM, Schlett CL, O'Donnell CJ, Hoffmann U, Fox CS, Peri-Aortic fat, cardiovascular disease risk factors, and aortic calcification: the Framingham Heart Study. Atherosclerosis 2010 210 656 661. doi: 10.1016/j.atherosclerosis.2010.01.007
132. Margaritis M, Antonopoulos AS, Digby J, Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation 2013 127 2209 2221. doi: 10.1161/CIRCULATIONAHA.112.001133
133. Löhn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM, Periadventitial fat releases a vascular relaxing factor. FASEB J 2002 16 1057 1063. doi: 10.1096/fj.02-0024com
134. Henrichot E, Juge-Aubry CE, Pernin A, Pache JC, Velebit V, Dayer JM, Meda P, Chizzolini C, Meier CA, Production of chemokines by perivascular adipose tissue: A role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol 2005 25 2594 2599. doi: 10.1161/01.ATV.0000188508.40052.35
135. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM, Positional cloning of the mouse obese gene and its human homologue. Nature 1994 372 425 432. doi: 10.1038/372425a0
136. Purdham DM, Zou MX, Rajapurohitam V, Karmazyn M, Rat heart is a site of leptin production and action. Am J Physiol Heart Circ Physiol 2004 287 H2877 H2884. doi: 10.1152/ajpheart.00499.2004
137. Friedman JM, Halaas JL, Leptin and the regulation of body weight in mammals. Nature 1998 395 763 770. doi: 10.1038/27376
138. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F, Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995 269 540 543
139. Santos-Alvarez J, Goberna R, Sánchez-Margalet V, Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol 1999 194 6 11. doi: 10.1006/cimm.1999.1490
140. Surmi BK, Atkinson RD, Gruen ML, Coenen KR, Hasty AH, The role of macrophage leptin receptor in aortic root lesion formation. Am J Physiol Endocrinol Metab 2008 294 E488 E495. doi: 10.1152/ajpendo.00374.2007
141. Kiguchi N, Maeda T, Kobayashi Y, Fukazawa Y, Kishioka S, Leptin enhances CC-chemokine ligand expression in cultured murine macrophage. Biochem Biophys Res Commun 2009 384 311 315. doi: 10.1016/j.bbrc.2009.04.121
142. Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, Ng A, Nicola NA, Alexander WS, Hilton DJ, Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci U S A 1996 93 14564 14568
143. Caldefie-Chezet F, Poulin A, Vasson MP, Leptin regulates functional capacities of polymorphonuclear neutrophils. Free Radic Res 2003 37 809 814
144. Tian Z, Sun R, Wei H, Gao B, Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun 2002 298 297 302
145. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI, Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998 394 897 901. doi: 10.1038/29795
146. De Rosa V, Procaccini C, Calì G, Pirozzi G, Fontana S, Zappacosta S, La Cava A, Matarese G, A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007 26 241 255. doi: 10.1016/j.immuni.2007.01.011
147. Bouloumie A, Marumo T, Lafontan M, Busse R, Leptin induces oxidative stress in human endothelial cells. FASEB J 1999 13 1231 1238
148. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzmán M, Brownlee M, Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001 276 25096 25100. doi: 10.1074/jbc.M007383200
149. Li L, Mamputu JC, Wiernsperger N, Renier G, Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes 2005 54 2227 2234
150. Hongo S, Watanabe T, Arita S, Kanome T, Kageyama H, Shioda S, Miyazaki A, Leptin modulates ACAT1 expression and cholesterol efflux from human macrophages. Am J Physiol Endocrinol Metab 2009 297 E474 E482. doi: 10.1152/ajpendo.90369.2008
151. O'Rourke L, Gronning LM, Yeaman SJ, Shepherd PR, Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem 2002 277 42557 42562. doi: 10.1074/jbc.M202151200
152. Hasty AH, Shimano H, Osuga J, Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 2001 276 37402 37408. doi: 10.1074/jbc.M010176200
153. Mertens A, Verhamme P, Bielicki JK, Phillips MC, Quarck R, Verreth W, Stengel D, Ninio E, Navab M, Mackness B, Mackness M, Holvoet P, Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003 107 1640 1646. doi: 10.1161/01.CIR.0000056523.08033.9F.
154. Wang J, Perrard XD, Perrard JL, Mukherjee A, Rosales C, Chen Y, Smith CW, Pownall HJ, Ballantyne CM, Wu H, ApoE and the role of very low density lipoproteins in adipose tissue inflammation. Atherosclerosis 2012 223 342 349. doi: 10.1016/j.atherosclerosis.2012.06.003
155. Chiba T, Shinozaki S, Nakazawa T, Kawakami A, Ai M, Kaneko E, Kitagawa M, Kondo K, Chait A, Shimokado K, Leptin deficiency suppresses progression of atherosclerosis in apoE-deficient mice. Atherosclerosis 2008 196 68 75. doi: 10.1016/j.atherosclerosis.2007.01.040
156. Wu KK, Wu TJ, Chin J, Mitnaul LJ, Hernandez M, Cai TQ, Ren N, Waters MG, Wright SD, Cheng K, Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. Atherosclerosis 2005 181 251 259. doi: 10.1016/j.atherosclerosis.2005.01.029
157. Bodary PF, Gu S, Shen Y, Hasty AH, Buckler JM, Eitzman DT, Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005 25 e119 e122. doi: 10.1161/01.ATV.0000173306.47722.ec.
158. Zeadin M, Butcher M, Werstuck G, Khan M, Yee CK, Shaughnessy SG, Effect of leptin on vascular calcification in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2009 29 2069 2075. doi: 10.1161/ATVBAHA.109.195255
159. Taleb S, Herbin O, Ait-Oufella H, Verreth W, Gourdy P, Barateau V, Merval R, Esposito B, Clément K, Holvoet P, Tedgui A, Mallat Z, Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler Thromb Vasc Biol 2007 27 2691 2698. doi: 10.1161/ATVBAHA.107.149567
160. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, Rader DJ, Kimmel SE, Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004 89 3872 3878. doi: 10.1210/jc.2003-031676
161. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, Rizzon P, Giorgino R, De Pergola G, Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001 25 805 810. doi: 10.1038/sj.ijo.0801623
162. Atabek ME, Kurtoglu S, Demir F, Baykara M, Relation of serum leptin and insulin-like growth factor-1 levels to intima-media thickness and functions of common carotid artery in children and adolescents with type 1 diabetes. Acta Paediatr 2004 93 1052 1057
163. Söderberg S, Ahrén B, Jansson JH, Johnson O, Hallmans G, Asplund K, Olsson T, Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999 246 409 418
164. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, Gami AS, Sert Kuniyoshi FH, Wolk R, Somers VK, Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am J Cardiol 2007 100 234 239. doi: 10.1016/j.amjcard.2007.02.088
165. Wallerstedt SM, Eriksson AL, Niklason A, Ohlsson C, Hedner T, Serum leptin and myocardial infarction in hypertension. Blood Press 2004 13 243 246
166. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N, Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001 104 3052 3056
167. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK, Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004 44 1819 1824. doi: 10.1016/j.jacc.2004.07.050
168. Couillard C, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ, Després JP, Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care 1998 21 782 786
169. Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini MP, Costantino F, Ruotolo G, Luzi L, Perseghin G, Fasting plasma leptin, tumor necrosis factor-Alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-Tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 2003 26 2883 2889
170. McGaffin KR, Moravec CS, McTiernan CF, Leptin signaling in the failing and mechanically unloaded human heart. Circ Heart Fail 2009 2 676 683. doi: 10.1161/CIRCHEARTFAILURE.109.869909
171. McGaffin KR, Witham WG, Yester KA, Romano LC, O'Doherty RM, McTiernan CF, O'Donnell CP, Cardiac-specific leptin receptor deletion exacerbates ischaemic heart failure in mice. Cardiovasc Res 2011 89 60 71. doi: 10.1093/cvr/cvq288
172. McGaffin KR, Zou B, McTiernan CF, O'Donnell CP, Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res 2009 83 313 324. doi: 10.1093/cvr/cvp071
173. Smith CC, Dixon RA, Wynne AM, Theodorou L, Ong SG, Subrayan S, Davidson SM, Hausenloy DJ, Yellon DM, Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol 2010 299 H1265 H1270. doi: 10.1152/ajpheart.00092.2010
174. Smith CC, Mocanu MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM, Leptin, the obesity-Associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol 2006 149 5 13. doi: 10.1038/sj.bjp.0706834
175. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW, Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-Alpha, in vivo. J Clin Endocrinol Metab 1997 82 4196 4200. doi: 10.1210/jcem.82.12.4450
176. Harkins JM, Moustaid-Moussa N, Chung YJ, Penner KM, Pestka JJ, North CM, Claycombe KJ, Expression of interleukin-6 is greater in preadipocytes than in adipocytes of 3T3-L1 cells and C57BL/6J and ob/ob mice. J Nutr 2004 134 2673 2677
177. Fried SK, Bunkin DA, Greenberg AS, Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998 83 847 850. doi: 10.1210/jcem.83.3.4660
178. Cartier A, Lemieux I, Alméras N, Tremblay A, Bergeron J, Després JP, Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-Alpha in men. J Clin Endocrinol Metab 2008 93 1931 1938. doi: 10.1210/jc.2007-2191
179. Heinrich PC, Castell JV, Andus T, Interleukin-6 and the acute phase response. Biochem J 1990 265 621 636
180. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Köhler G, Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994 368 339 342. doi: 10.1038/368339a0
181. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V, Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994 180 1243 1250
182. Chen Q, Fisher DT, Clancy KA, Gauguet JM, Wang WC, Unger E, Rose-John S, von Andrian UH, Baumann H, Evans SS, Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol 2006 7 1299 1308. doi: 10.1038/ni1406
183. Chen Q, Wang WC, Bruce R, Li H, Schleider DM, Mulbury MJ, Bain MD, Wallace PK, Baumann H, Evans SS, Central role of IL-6 receptor signal-Transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress. Immunity 2004 20 59 70
184. Chomarat P, Banchereau J, Davoust J, Palucka AK, IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000 1 510 514. doi: 10.1038/82763
185. Kopf M, Herren S, Wiles MV, Pepys MB, Kosco-Vilbois MH, Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med 1998 188 1895 1906
186. McLoughlin RM, Jenkins BJ, Grail D, Williams AS, Fielding CA, Parker CR, Ernst M, Topley N, Jones SA, IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 2005 102 9589 9594. doi: 10.1073/pnas.0501794102
187. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R, Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996 274 1379 1383
188. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK, IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998 101 311 320. doi: 10.1172/JCI1368
189. Mauer J, Chaurasia B, Goldau J, Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-Associated resistance to insulin. Nat Immunol 2014 15 423 430. doi: 10.1038/ni.2865
190. Senn JJ, Klover PJ, Nowak IA, Mooney RA, Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002 51 3391 3399
191. Yuen DY, Dwyer RM, Matthews VB, Zhang L, Drew BG, Neill B, Kingwell BA, Clark MG, Rattigan S, Febbraio MA, Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-Alpha expression. Diabetes 2009 58 1086 1095. doi: 10.2337/db08-0775
192. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA, Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-Activated protein kinase. Diabetes 2006 55 2688 2697. doi: 10.2337/db05-1404
193. Weigert C, Hennige AM, Brodbeck K, Haring HU, Schleicher ED, Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt. Am J Physiol Endocrinol Metab 2005 289 E251 E257
194. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH, Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000 101 1767 1772
195. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V, Long-Term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008 5 e78. doi: 10.1371/journal.pmed.0050078
196. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P, PRIME Study Group C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003 23 1255 1261. doi: 10.1161/01.ATV.0000079512.66448.1D.
197. Ridker PM, Hennekens CH, Buring JE, Rifai N, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000 342 836 843. doi: 10.1056/NEJM200003233421202
198. Interleukin-6 Receptor Mendelian Randomisation Analysis Consortium The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. Lancet 2012 379 1214 1224
199. IL6R Genetics Consortium Emerging Risk Factors Collaboration Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-Analysis of 82 studies. Lancet 2012 379 1205 1213
200. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R, Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999 19 2364 2367
201. Schieffer B, Selle T, Hilfiker A, Hilfiker-Kleiner D, Grote K, Tietge UJ, Trautwein C, Luchtefeld M, Schmittkamp C, Heeneman S, Daemen MJ, Drexler H, Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 2004 110 3493 3500. doi: 10.1161/01.CIR.0000148135.08582.97
202. Elhage R, Clamens S, Besnard S, Mallat Z, Tedgui A, Arnal J, Maret A, Bayard F, Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis 2001 156 315 320
203. Song L, Schindler C, IL-6 and the acute phase response in murine atherosclerosis. Atherosclerosis 2004 177 43 51. doi: 10.1016/j.atherosclerosis.2004.06.018
204. Frisdal E, Lesnik P, Olivier M, Robillard P, Chapman MJ, Huby T, Guerin M, Le Goff W, Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the proinflammatory response. J Biol Chem 2011 286 30926 30936. doi: 10.1074/jbc.M111.264325
205. Robert J, Lehner M, Frank S, Perisa D, von Eckardstein A, Rohrer L, Interleukin 6 stimulates endothelial binding and transport of high-density lipoprotein through induction of endothelial lipase. Arterioscler Thromb Vasc Biol 2013 33 2699 2706. doi: 10.1161/ATVBAHA.113.301363
206. Schuett H, Oestreich R, Waetzig GH, Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2012 32 281 290. doi: 10.1161/ATVBAHA.111.229435
207. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL, Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996 27 1201 1206. doi: 10.1016/0735-1097(95)00589-7
208. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM, Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996 77 723 727
209. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S, Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997 79 1128 1131
210. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M, Kinoshita M, Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998 31 391 398
211. Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK, Nordøy I, Aass H, Espevik T, Simonsen S, Frøland SS, Gullestad L, Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999 83 376 382
212. Fuchs M, Hilfiker A, Kaminski K, Hilfiker-Kleiner D, Guener Z, Klein G, Podewski E, Schieffer B, Rose-John S, Drexler H, Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J 2003 17 2118 2120. doi: 10.1096/fj.03-0331fje
213. Kobara M, Noda K, Kitamura M, Okamoto A, Shiraishi T, Toba H, Matsubara H, Nakata T, Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice. Cardiovasc Res 2010 87 424 430. doi: 10.1093/cvr/cvq078
214. Matsushita K, Iwanaga S, Oda T, Kimura K, Shimada M, Sano M, Umezawa A, Hata J, Ogawa S, Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab Invest 2005 85 1210 1223. doi: 10.1038/labinvest.3700322
215. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA, The hormone resistin links obesity to diabetes. Nature 2001 409 307 312. doi: 10.1038/35053000
216. Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS, Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004 53 1671 1679
217. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA, Regulation of fasted blood glucose by resistin. Science 2004 303 1195 1198. doi: 10.1126/science.1092341
218. Qi Y, Nie Z, Lee YS, Singhal NS, Scherer PE, Lazar MA, Ahima RS, Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 2006 55 3083 3090. doi: 10.2337/db05-0615
219. Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW, Scherer PE, Rossetti L, Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004 114 232 9
220. Chen BH, Song Y, Ding EL, Roberts CK, Manson JE, Rifai N, Buring JE, Gaziano JM, Liu S, Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 2009 32 329 334. doi: 10.2337/dc08-1625
221. Heidemann C, Sun Q, van Dam RM, Meigs JB, Zhang C, Tworoger SS, Mantzoros CS, Hu FB, Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 2008 149 307 316
222. Hivert MF, Sullivan LM, Fox CS, Nathan DM, D'Agostino RB Sr, Wilson PW, Meigs JB, Associations of adiponectin, resistin, and tumor necrosis factor-Alpha with insulin resistance. J Clin Endocrinol Metab 2008 93 3165 3172. doi: 10.1210/jc.2008-0425
223. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS, Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003 88 4848 4856. doi: 10.1210/jc.2003-030519
224. Menzaghi C, Coco A, Salvemini L, Thompson R, De Cosmo S, Doria A, Trischitta V, Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. J Clin Endocrinol Metab 2006 91 2792 2795. doi: 10.1210/jc.2005-2715
225. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, Cho YM, Park YJ, Kim SY, Lee HK, Park KS, Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004 89 150 156. doi: 10.1210/jc.2003-031121
226. Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, Xiao Q, Mistry JS, Retzlaff BM, Knopp RH, Kahn SE, Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005 48 2330 2333. doi: 10.1007/s00125-005-1932-y.
227. Kim KH, Lee K, Moon YS, Sul HS, A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001 276 11252 11256. doi: 10.1074/jbc.C100028200
228. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA, Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003 300 472 476
229. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S, Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-Activated receptor-gamma action in humans. Diabetes 2001 50 2199 2202
230. Lu SC, Shieh WY, Chen CY, Hsu SC, Chen HL, Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett 2002 530 158 162
231. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR, Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003 309 286 290
232. Kunnari AM, Savolainen ER, Ukkola OH, Kesäniemi YA, Jokela MA, The expression of human resistin in different leucocyte lineages is modulated by LPS and TNFalpha. Regul Pept 2009 157 57 63. doi: 10.1016/j.regpep.2009.05.002
233. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A, Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004 27 2450 2457
234. Qi Q, Wang J, Li H, Yu Z, Ye X, Hu FB, Franco OH, Pan A, Liu Y, Lin X, Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-Aged and older Chinese. Eur J Endocrinol 2008 159 585 593. doi: 10.1530/EJE-08-0427
235. Fargnoli JL, Sun Q, Olenczuk D, Qi L, Zhu Y, Hu FB, Mantzoros CS, Resistin is associated with biomarkers of inflammation while total and high-molecular weight adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. Eur J Endocrinol 2010 162 281 288. doi: 10.1530/EJE-09-0555
236. Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, Pagano GF, Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 2005 29 1315 1320. doi: 10.1038/sj.ijo.0803037
237. Kunnari A, Ukkola O, Päivänsalo M, Kesäniemi YA, High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 2006 91 2755 2760. doi: 10.1210/jc.2005-2115
238. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA, Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003 108 736 740. doi: 10.1161/01.CIR.0000084503.91330.49
239. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ, Human resistin stimulates the pro-inflammatory cytokines TNF-Alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005 334 1092 1101. doi: 10.1016/j.bbrc.2005.06.202
240. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A, Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005 174 5789 5795
241. Cho Y, Lee SE, Lee HC, Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. J Am Coll Cardiol 2011 57 99 109. doi: 10.1016/j.jacc.2010.07.035
242. Asterholm IW, Rutkowski JM, Fujikawa T, Cho YR, Fukuda M, Tao C, Wang ZV, Gupta RK, Elmquist JK, Scherer PE, Elevated resistin levels induce central leptin resistance and increased atherosclerotic progression in mice. Diabetologia 2014 57 1209 1218. doi: 10.1007/s00125-014-3210-3
243. Yaturu S, Daberry RP, Rains J, Jain S, Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. Cytokine 2006 34 219 223. doi: 10.1016/j.cyto.2006.05.005
244. Lim S, Koo BK, Cho SW, Kihara S, Funahashi T, Cho YM, Kim SY, Lee HK, Shimomura I, Park KS, Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): A 42-month prospective study. Atherosclerosis 2008 196 398 404. doi: 10.1016/j.atherosclerosis.2006.11.017
245. Luc G, Empana JP, Morange P, Juhan-Vague I, Arveiler D, Ferrieres J, Amouyel P, Evans A, Kee F, Bingham A, Machez E, Ducimetiere P, Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study. Int J Obes (Lond) 2010 34 118 126. doi: 10.1038/ijo.2009.204
246. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ, Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005 111 932 939. doi: 10.1161/01.CIR.0000155620.10387.43
247. Muse ED, Feldman DI, Blaha MJ, Dardari ZA, Blumenthal RS, Budoff MJ, Nasir K, Criqui MH, Cushman M, McClelland RL, Allison MA, The association of resistin with cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2015 239 101 108
248. Ohmori R, Momiyama Y, Kato R, Taniguchi H, Ogura M, Ayaori M, Nakamura H, Ohsuzu F, Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005 46 379 380. doi: 10.1016/j.jacc.2005.04.022
249. Pischon T, Bamberger CM, Kratzsch J, Zyriax BC, Algenstaedt P, Boeing H, Windler E, Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005 13 1764 1771. doi: 10.1038/oby.2005.215
250. Hu WL, Qiao SB, Hou Q, Yuan JS, Plasma resistin is increased in patients with unstable angina. Chin Med J (Engl) 2007 120 871 875
251. Wang H, Chen DY, Cao J, He ZY, Zhu BP, Long M, High serum resistin level may be an indicator of the severity of coronary disease in acute coronary syndrome. Chin Med Sci J 2009 24 161 166
252. Sinan UY, Canbolat IP, Baydar O, Oktay V, Imre G, Kocas C, Abaci O, Coskun U, Bostan C, Kilickesmez KO, Yildiz A, Kaya A, Gurmen T, Yigit Z, Relationship between increased serum resistin level and severity of coronary artery disease. Angiology 2014 65 239 242. doi: 10.1177/0003319713502718
253. Momiyama Y, Ohmori R, Uto-Kondo H, Tanaka N, Kato R, Taniguchi H, Arakawa K, Nakamura H, Ohsuzu F, Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb 2011 18 108 114
254. Kreçki R, Krzemińska-Pakuła M, Peruga JZ, Szcześniak P, Lipiec P, Wierzbowska-Drabik K, Orszulak-Michalak D, Kasprzak JD, Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up. Med Sci Monit 2011 17 CR26 CR32
255. Lubos E, Messow CM, Schnabel R, Rupprecht HJ, Espinola-Klein C, Bickel C, Peetz D, Post F, Lackner KJ, Tiret L, Münzel T, Blankenberg S, Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007 193 121 128. doi: 10.1016/j.atherosclerosis.2006.05.039
256. Chu S, Ding W, Li K, Pang Y, Tang C, Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 2008 72 1249 1253
257. Langheim S, Dreas L, Veschini L, Maisano F, Foglieni C, Ferrarello S, Sinagra G, Zingone B, Alfieri O, Ferrero E, Maseri A, Ruotolo G, Increased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndrome. Am J Physiol Heart Circ Physiol 2010 298 H746 H753. doi: 10.1152/ajpheart.00617.2009
258. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y, Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003 107 671 674
259. Arita Y, Kihara S, Ouchi N, Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999 257 79 83
260. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T, Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004 68 975 981
261. Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, Möhlig M, Pfeiffer AF, Luft FC, Sharma AM, Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003 52 942 947
262. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM, Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 2004 13 236 242
263. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y, Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999 100 2473 2476
264. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y, Osaka CAD Study Group. Coronary artery disease Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003 23 85 89
265. Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, Kataoka T, Kamimori K, Shimodozono S, Kobayashi Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004 90 528 533
266. Kojima S, Funahashi T, Sakamoto T, The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 2003 89 667
267. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB, Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004 291 1730 1737. doi: 10.1001/jama.291.14.1730
268. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB, Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005 54 534 539
269. Ai M, Otokozawa S, Asztalos BF, White CC, Cupples LA, Nakajima K, Lamon-Fava S, Wilson PW, Matsuzawa Y, Schaefer EJ, Adiponectin: An independent risk factor for coronary heart disease in men in the Framingham offspring Study. Atherosclerosis 2011 217 543 548. doi: 10.1016/j.atherosclerosis.2011.05.035
270. Lindsay RS, Resnick HE, Zhu J, Tun ML, Howard BV, Zhang Y, Yeh J, Best LG, Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005 25 e15 e16. doi: 10.1161/01.ATV.0000153090.21990.8c.
271. Lawlor DA, Davey Smith G, Ebrahim S, Thompson C, Sattar N, Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005 90 5677 5683. doi: 10.1210/jc.2005-0825
272. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, Danesh J, Whincup PH, Adiponectin and coronary heart disease: A prospective study and meta-Analysis. Circulation 2006 114 623 629. doi: 10.1161/CIRCULATIONAHA.106.618918
273. Walkey AJ, Rice TW, Konter J, Ouchi N, Shibata R, Walsh K, deBoisblanc BP, Summer R, Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure. Crit Care Med 2010 38 2329 2334. doi: 10.1097/CCM.0b013e3181fa0561
274. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P, Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005 112 1756 1762. doi: 10.1161/CIRCULATIONAHA.104.530972
275. Fantuzzi G, Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 2008 121 326 330. doi: 10.1016/j.jaci.2007.10.018
276. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K, Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005 11 1096 1103. doi: 10.1038/nm1295
277. Ohashi K, Ouchi N, Sato K, Higuchi A, Ishikawa TO, Herschman HR, Kihara S, Walsh K, Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol Cell Biol 2009 29 3487 3499. doi: 10.1128/MCB.00126-09.
278. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K, Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004 10 1384 1389. doi: 10.1038/nm1137
279. Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, Hori M, Matsuzawa Y, Funahashi T, Kitakaze M, Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005 67 705 713. doi: 10.1016/j.cardiores.2005.04.018
280. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, Funahashi T, Matsuzawa Y, Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004 94 e27 e31. doi: 10.1161/01.RES.0000119921.86460.37
281. Kondo M, Shibata R, Miura R, Shimano M, Kondo K, Li P, Ohashi T, Kihara S, Maeda N, Walsh K, Ouchi N, Murohara T, Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of endothelial nitric-oxide synthase. J Biol Chem 2009 284 1718 1724. doi: 10.1074/jbc.M805301200
282. Kubota N, Terauchi Y, Yamauchi T, Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002 277 25863 25866. doi: 10.1074/jbc.C200251200
283. Matsuda M, Shimomura I, Sata M, Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002 277 37487 37491. doi: 10.1074/jbc.M206083200
284. Nishimura M, Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C, Shin HK, Moskowitz MA, Ouchi N, Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 2008 117 216 223. doi: 10.1161/CIRCULATIONAHA.107.725044
285. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, Funahashi T, Walsh K, Adiponectin stimulates angiogenesis by promoting cross-Talk between AMP-Activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004 279 1304 1309. doi: 10.1074/jbc.M310389200
286. Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K, Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-Activated protein kinase signaling. J Biol Chem 2004 279 28670 28674. doi: 10.1074/jbc.M402558200
287. Shinmura K, Tamaki K, Saito K, Nakano Y, Tobe T, Bolli R, Cardioprotective effects of short-Term caloric restriction are mediated by adiponectin via activation of AMP-Activated protein kinase. Circulation 2007 116 2809 2817. doi: 10.1161/CIRCULATIONAHA.107.725697
288. Ikeda Y, Ohashi K, Shibata R, Pimentel DR, Kihara S, Ouchi N, Walsh K, Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes. FEBS Lett 2008 582 1147 1150. doi: 10.1016/j.febslet.2008.03.002
289. Holland WL, Miller RA, Wang ZV, Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011 17 55 63. doi: 10.1038/nm.2277
290. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ, Ma XL, Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007 115 1408 1416. doi: 10.1161/CIRCULATIONAHA.106.666941
291. Kondo K, Shibata R, Unno K, Shimano M, Ishii M, Kito T, Shintani S, Walsh K, Ouchi N, Murohara T, Impact of a single intracoronary administration of adiponectin on myocardial ischemia/reperfusion injury in a pig model. Circ Cardiovasc Interv 2010 3 166 173. doi: 10.1161/CIRCINTERVENTIONS.109.872044
292. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y, Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000 96 1723 1732
293. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME, Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004 316 924 929. doi: 10.1016/j.bbrc.2004.02.130
294. Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M, Nonaka K, Saito T, Hanazawa S, Yamashita Y, Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 2005 579 6821 6826. doi: 10.1016/j.febslet.2005.11.019
295. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y, Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004 109 2046 2049. doi: 10.1161/01.CIR.0000127953.98131.ED.
296. Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, Pedersen AA, Kalthoff C, Tullin S, Sams A, Summer R, Walsh K, Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010 285 6153 6160. doi: 10.1074/jbc.M109.088708
297. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, Kihara S, Walsh K, Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 2007 117 375 386. doi: 10.1172/JCI29709
298. Ouchi N, Kihara S, Arita Y, Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001 103 1057 1063
299. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y, Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002 106 2767 2770
300. Yamauchi T, Kamon J, Waki H, Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003 278 2461 2468. doi: 10.1074/jbc.M209033200
301. van Stijn CM, Kim J, Barish GD, Tietge UJ, Tangirala RK, Adiponectin expression protects against angiotensin II-mediated inflammation and accelerated atherosclerosis. PLoS One 2014 9 e86404. doi: 10.1371/journal.pone.0086404
302. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, Sukhova GK, Colvin RA, Kihara S, Funahashi T, Luster AD, Libby P, Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008 102 218 225. doi: 10.1161/CIRCRESAHA.107.164988
303. Nawrocki AR, Hofmann SM, Teupser D, Basford JE, Durand JL, Jelicks LA, Woo CW, Kuriakose G, Factor SM, Tanowitz HB, Hui DY, Tabas I, Scherer PE, Lack of association between adiponectin levels and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2010 30 1159 1165. doi: 10.1161/ATVBAHA.109.195826
304. Yamauchi T, Kamon J, Ito Y, Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003 423 762 769. doi: 10.1038/nature01705
305. Parker-Duffen JL, Nakamura K, Silver M, Zuriaga MA, MacLauchlan S, Aprahamian TR, Walsh K, Divergent roles for adiponectin receptor 1 (AdipoR1) and AdipoR2 in mediating revascularization and metabolic dysfunction in vivo. J Biol Chem 2014 289 16200 16213. doi: 10.1074/jbc.M114.548115
306. Bjursell M, Ahnmark A, Bohlooly-Y M, William-Olsson L, Rhedin M, Peng XR, Ploj K, Gerdin AK, Arnerup G, Elmgren A, Berg AL, Oscarsson J, Lindén D, Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 2007 56 583 593. doi: 10.2337/db06-1432
307. Liu Y, Michael MD, Kash S, Bensch WR, Monia BP, Murray SF, Otto KA, Syed SK, Bhanot S, Sloop KW, Sullivan JM, Reifel-Miller A, Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. Endocrinology 2007 148 683 692. doi: 10.1210/en.2006-0708
308. Fujioka D, Kawabata K, Saito Y, Kobayashi T, Nakamura T, Kodama Y, Takano H, Obata JE, Kitta Y, Umetani K, Kugiyama K, Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am J Physiol Heart Circ Physiol 2006 290 H2409 H2416. doi: 10.1152/ajpheart.00987.2005
309. Wright JR, Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005 5 58 68. doi: 10.1038/nri1528
310. Galvan MD, Hulsebus H, Heitker T, Zeng E, Bohlson SS, Complement protein C1q and adiponectin stimulate Mer tyrosine kinase-dependent engulfment of apoptotic cells through a shared pathway. J Innate Immun 2014 6 780 792. doi: 10.1159/000363295
311. Nakatsuji H, Kobayashi H, Kishida K, Nakagawa T, Takahashi S, Tanaka H, Akamatsu S, Funahashi T, Shimomura I, Binding of adiponectin and C1q in human serum, and clinical significance of the measurement of C1q-Adiponectin / total adiponectin ratio. Metabolism 2013 62 109 120. doi: 10.1016/j.metabol.2012.06.006
312. Denzel MS, Hebbard LW, Shostak G, Shapiro L, Cardiff RD, Ranscht B, Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin Cancer Res 2009 15 3256 3264. doi: 10.1158/1078-0432.CCR-08-2661
313. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B, T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010 120 4342 4352. doi: 10.1172/JCI43464
314. Parker-Duffen JL, Nakamura K, Silver M, Kikuchi R, Tigges U, Yoshida S, Denzel MS, Ranscht B, Walsh K, T-cadherin is essential for adiponectin-mediated revascularization. J Biol Chem 2013 288 24886 24897. doi: 10.1074/jbc.M113.454835
315. Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Revett T, Gimeno R, Lodish HF, Molecular, biochemical and functional characterizations of C1q/TNF family members: Adipose-Tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J 2008 416 161 177. doi: 10.1042/BJ20081240
316. Deng W, Li C, Zhang Y, Zhao J, Yang M, Tian M, Li L, Zheng Y, Chen B, Yang G, Serum C1q/TNF-related protein-3 (CTRP3) levels are decreased in obesity and hypertension and are negatively correlated with parameters of insulin resistance. Diabetol Metab Syndr 2015 7 33. doi: 10.1186/s13098-015-0029-0
317. Kambara T, Ohashi K, Shibata R, Ogura Y, Maruyama S, Enomoto T, Uemura Y, Shimizu Y, Yuasa D, Matsuo K, Miyabe M, Kataoka Y, Murohara T, Ouchi N, CTRP9 protein protects against myocardial injury following ischemia-reperfusion through AMP-Activated protein kinase (AMPK)-dependent mechanism. J Biol Chem 2012 287 18965 18973. doi: 10.1074/jbc.M112.357939
318. Peterson JM, Wei Z, Wong GW, C1q/TNF-related protein-3 (CTRP3), a novel adipokine that regulates hepatic glucose output. J Biol Chem 2010 285 39691 39701. doi: 10.1074/jbc.M110.180695
319. Wolf RM, Steele KE, Peterson LA, Magnuson TH, Schweitzer MA, Wong GW, Lower Circulating C1q/TNF-Related Protein-3 (CTRP3) Levels Are Associated with Obesity: A Cross-Sectional Study. PLoS One 2015 10 e0133955. doi: 10.1371/journal.pone.0133955
320. Ouchi N, Walsh K, Cardiovascular and metabolic regulation by the adiponectin/C1q/tumor necrosis factor-related protein family of proteins. Circulation 2012 125 3066 3068. doi: 10.1161/CIRCULATIONAHA.112.114181
321. Sun Y, Yi W, Yuan Y, Lau WB, Yi D, Wang X, Wang Y, Su H, Wang X, Gao E, Koch WJ, Ma XL, C1q/tumor necrosis factor-related protein-9, a novel adipocyte-derived cytokine, attenuates adverse remodeling in the ischemic mouse heart via protein kinase A activation. Circulation 2013 128 S113 S120. doi: 10.1161/CIRCULATIONAHA.112.000010
322. Su H, Yuan Y, Wang XM, Lau WB, Wang Y, Wang X, Gao E, Koch WJ, Ma XL, Inhibition of CTRP9, a novel and cardiac-Abundantly expressed cell survival molecule, by TNFα-initiated oxidative signaling contributes to exacerbated cardiac injury in diabetic mice. Basic Res Cardiol 2013 108 315. doi: 10.1007/s00395-012-0315-z.
323. Kambara T, Shibata R, Ohashi K, Matsuo K, Hiramatsu-Ito M, Enomoto T, Yuasa D, Ito M, Hayakawa S, Ogawa H, Aprahamian T, Walsh K, Murohara T, Ouchi N, C1q/tumor necrosis factor-related protein 9 protects against acute myocardial injury through an adiponectin receptor I-AMPK-dependent mechanism. Mol Cell Biol 2015 35 2173 2185. doi: 10.1128/MCB.01518-14
324. Yi W, Sun Y, Yuan Y, Lau WB, Zheng Q, Wang X, Wang Y, Shang X, Gao E, Koch WJ, Ma XL, C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation 2012 125 3159 3169. doi: 10.1161/CIRCULATIONAHA.112.099937
325. Wu D, Lei H, Wang JY, Zhang CL, Feng H, Fu FY, Li L, Wu LL, CTRP3 attenuates post-infarct cardiac fibrosis by targeting Smad3 activation and inhibiting myofibroblast differentiation. J Mol Med (Berl) 2015 93 (12) 1311 1325. doi: 10.1007/s00109-015-1309-8
326. Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Choi DS, Baik SH, Blüher M, Youn BS, Choi KM, Implication of progranulin and C1q/TNF-related protein-3 (CTRP3) on inflammation and atherosclerosis in subjects with or without metabolic syndrome. PLoS One 2013 8 e55744. doi: 10.1371/journal.pone.0055744
327. Tsuji S, Yamashita M, Nishiyama A, Shinohara T, Li Z, Myrvik QN, Hoffman DR, Henriksen RA, Shibata Y, Differential structure and activity between human and mouse intelectin-1: human intelectin-1 is a disulfide-linked trimer, whereas mouse homologue is a monomer. Glycobiology 2007 17 1045 1051. doi: 10.1093/glycob/cwm075
328. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW, Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006 290 E1253 E1261. doi: 10.1152/ajpendo.00572.2004
329. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC, Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007 56 1655 1661. doi: 10.2337/db06-1506
330. Pan HY, Guo L, Li Q, Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010 88 29 33. doi: 10.1016/j.diabres.2010.01.013
331. Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, Higuchi A, Terasaki H, Kihara S, Murohara T, Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012 4 37. doi: 10.1186/1758-5996-4-37
332. Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T, Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011 219 811 814. doi: 10.1016/j.atherosclerosis.2011.08.017
333. Onur I, Oz F, Yildiz S, Oflaz H, Sigirci S, Elitok A, Pilten S, Karaayvaz EB, Cizgici AY, Kaya MG, Onur ST, Sahin I, Dinckal HM, Serum omentin 1 level is associated with coronary artery disease and its severity in postmenopausal women. Angiology 2014 65 896 900. doi: 10.1177/0003319713511322
334. Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, Chen FQ, Shang DY, Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin 2011 32 873 878. doi: 10.1038/aps.2011.26
335. Shang FJ, Wang JP, Liu XT, Zheng QS, Xue YS, Wang B, Zhao LY, Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers 2011 16 657 662. doi: 10.3109/1354750X.2011.622789
336. Shibata R, Takahashi R, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T, Ouchi N, Association of a fat-derived plasma protein omentin with carotid artery intima-media thickness in apparently healthy men. Hypertens Res 2011 34 1309 1312. doi: 10.1038/hr.2011.130
337. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y, Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010 393 668 672. doi: 10.1016/j.bbrc.2010.02.053
338. Maruyama S, Shibata R, Kikuchi R, Izumiya Y, Rokutanda T, Araki S, Kataoka Y, Ohashi K, Daida H, Kihara S, Ogawa H, Murohara T, Ouchi N, Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2012 287 408 417. doi: 10.1074/jbc.M111.261818
339. Greulich S, Chen WJ, Maxhera B, Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One 2013 8 e59697. doi: 10.1371/journal.pone.0059697
340. Matsuo K, Shibata R, Ohashi K, Kambara T, Uemura Y, Hiramatsu-Ito M, Enomoto T, Yuasa D, Joki Y, Ito M, Hayakawa S, Ogawa H, Kihara S, Murohara T, Ouchi N, Omentin functions to attenuate cardiac hypertrophic response. J Mol Cell Cardiol 2015 79 195 202. doi: 10.1016/j.yjmcc.2014.11.019
341. Kataoka Y, Shibata R, Ohashi K, Omentin prevents myocardial ischemic injury through AMP-Activated protein kinase- and Akt-dependent mechanisms. J Am Coll Cardiol 2014 63 2722 2733. doi: 10.1016/j.jacc.2014.03.032
342. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y, Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011 408 339 343. doi: 10.1016/j.bbrc.2011.04.039
343. Hiramatsu-Ito M, Shibata R, Ohashi K, Omentin attenuates atherosclerotic lesion formation in apolipoprotein E-deficient mice. Cardiovasc Res 2016 110 107 117. doi: 10.1093/cvr/cvv282
344. Ouchi N, Higuchi A, Ohashi K, Oshima Y, Gokce N, Shibata R, Akasaki Y, Shimono A, Walsh K, Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010 329 454 457. doi: 10.1126/science.1188280
345. Nakamura K, Sano S, Fuster JJ, Kikuchi R, Shimizu I, Ohshima K, Katanasaka Y, Ouchi N, Walsh K, Secreted frizzled-related Protein 5 diminishes cardiac inflammation and protects the heart from ischemia/reperfusion injury. J Biol Chem 2016 291 2566 2575. doi: 10.1074/jbc.M115.693937
346. Prats-Puig A, Soriano-Rodríguez P, Carreras-Badosa G, Riera-Pérez E, Ros-Miquel M, Gomila-Borja A, de Zegher F, Ibáñez L, Bassols J, López-Bermejo A, Balanced duo of anti-inflammatory SFRP5 and proinflammatory WNT5A in children. Pediatr Res 2014 75 793 797. doi: 10.1038/pr.2014.29
347. Ehrlund A, Mejhert N, Lorente-Cebrián S, Aström G, Dahlman I, Laurencikiene J, Rydén M, Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue. J Clin Endocrinol Metab 2013 98 E503 E508. doi: 10.1210/jc.2012-3416
348. Hu Z, Deng H, Qu H, Plasma SFRP5 levels are decreased in Chinese subjects with obesity and type 2 diabetes and negatively correlated with parameters of insulin resistance. Diabetes Res Clin Pract 2013 99 391 395. doi: 10.1016/j.diabres.2012.11.026
349. Hu W, Li L, Yang M, Luo X, Ran W, Liu D, Xiong Z, Liu H, Yang G, Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab 2013 98 290 298. doi: 10.1210/jc.2012-2466
350. Tan X, Wang X, Chu H, Liu H, Yi X, Xiao Y, SFRP5 correlates with obesity and metabolic syndrome and increases after weight loss in children. Clin Endocrinol (Oxf) 2014 81 363 369. doi: 10.1111/cen.12361
351. Catalán V, Gómez-Ambrosi J, Rodríguez A, Pérez-Hernández AI, Gurbindo J, Ramírez B, Méndez-Giménez L, Rotellar F, Valentí V, Moncada R, Martí P, Sola I, Silva C, Salvador J, Frühbeck G, Activation of noncanonical Wnt signaling through WNT5A in visceral adipose tissue of obese subjects is related to inflammation. J Clin Endocrinol Metab 2014 99 E1407 E1417. doi: 10.1210/jc.2014-1191
352. Carstensen M, Herder C, Kempf K, Erlund I, Martin S, Koenig W, Sundvall J, Bidel S, Kuha S, Roden M, Tuomilehto J, Sfrp5 correlates with insulin resistance and oxidative stress. Eur J Clin Invest 2013 43 350 357. doi: 10.1111/eci.12052
353. Schulte DM, Müller N, Neumann K, Oberhäuser F, Faust M, Güdelhöfer H, Brandt B, Krone W, Laudes M, Pro-inflammatory wnt5a and anti-inflammatory sFRP5 are differentially regulated by nutritional factors in obese human subjects. PLoS One 2012 7 e32437. doi: 10.1371/journal.pone.0032437
354. Miyoshi T, Doi M, Usui S, Iwamoto M, Kajiya M, Takeda K, Nosaka K, Nakayama R, Okawa K, Takagi W, Nakamura K, Hirohata S, Ito H, Low serum level of secreted frizzled-related protein 5, an anti-inflammatory adipokine, is associated with coronary artery disease. Atherosclerosis 2014 233 454 459. doi: 10.1016/j.atherosclerosis.2014.01.019
355. Kim J, Kim J, Kim DW, Ha Y, Ihm MH, Kim H, Song K, Lee I, Wnt5a induces endothelial inflammation via beta-catenin-independent signaling. J Immunol 2010 185 1274 1282. doi: 10.4049/jimmunol.1000181
356. Christman MA II, Goetz DJ, Dickerson E, McCall KD, Lewis CJ, Benencia F, Silver MJ, Kohn LD, Malgor R, Wnt5a is expressed in murine and human atherosclerotic lesions. Am J Physiol Heart Circ Physiol 2008 294 H2864 H2870. doi: 10.1152/ajpheart.00982.2007
357. Breton-Romero R, Feng B, Holdbrook M, Farb MG, Fetterman JL, Linder EA, Berk BD, Masaki N, Weisbrod RM, Inagaki E, Gokce N, Fuster JJ, Walsh K, Hamburg N, Endothelial dysfunction in human diabetes is mediated by Wnt5a-JNK signaling. Arterioscler Thromb Vasc Biol 2016;36:561-569
358. Pereira C, Schaer DJ, Bachli EB, Kurrer MO, Schoedon G, Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol 2008 28 504 510. doi: 10.1161/ATVBAHA.107.157438